Journal article icon

Journal article

Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction

Abstract:
Severe early-onset fetal growth restriction (FGR) is an untreatable condition associated with substantial mortality and morbidity for the fetus and neonate. There has been growing interest in novel therapies such as nitric oxide donors and promotors to improve placental function and outcomes for these high-risk pregnancies. The UK STRIDER trial was designed to test the effectiveness of sildenafil (25 mg three times a day) versus placebo at prolonging gestation in severe early-onset FGR.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


Cornforth, C More by this author
Jackson, R More by this author
Harrold, J More by this author
Turner, MA More by this author
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Child and Adolescent Health Journal website
Volume:
3
Issue:
3
Pages:
e2-e3
Publication date:
2019-01-28
Acceptance date:
2019-01-14
DOI:
EISSN:
2352-4642
Pmid:
30704877
Pubs id:
977009
Local pid:
pubs:977009
Language:
English
Keywords:
Format:
Print-Electronic

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP